SCHEMBL4131664

SCHEMBL4131664

O=C1CCC(C2=CCc3ccccc32)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.38
ESR2 Q92731 2/20 0.37
PTPN1 P18031 2/20 0.37
PTPRC P08575 1/20 0.36
PTPRF P10586 1/20 0.36
CDC25B P30305 1/20 0.36
MAOA P21397 4/20 0.35
CYP2A6 P11509 2/20 0.35
MAOB P27338 2/20 0.35
CYP1A2 P05177 1/20 0.33
CYP19A1 P11511 1/20 0.33
PDPK1 O15530 1/20 0.33
PARP1 P09874 1/20 0.33
PARP10 Q53GL7 1/20 0.33
PARP11 Q9NR21 1/20 0.33
ACHE P22303 1/20 0.33
BCHE P06276 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16393502 0.85 HTR6 (0.37) CES1PTPN1PTPRCPTPRFCDC25B
SCHEMBL27546304 0.82 PTPN1 (0.44) PTPN1PTPRCPTPRFCDC25BMAOA
SCHEMBL16339665 0.80 PTPN1 (0.46) PTPN1PTPRCPTPRFCDC25BMAOA
SCHEMBL4139119 0.78 PARP1 (0.40) ESR2PARP1PARP10ACHE
SCHEMBL9636881 0.77 SLC18A3 (0.46) ACHEBCHE
SCHEMBL15551111 0.75 PTPN1 (0.53) CES1PTPN1PTPRCPTPRFCDC25B
SCHEMBL9366334 0.72 SLC18A3 (0.41) CES1PTPN1PTPRCPTPRFCDC25B
SCHEMBL18440342 0.71 CES1 (0.39) CES1PTPN1MAOACYP2A6MAOB
SCHEMBL8900291 0.70 NPC1 (0.39) CES1PTPN1PTPRCPTPRFCDC25B
SCHEMBL30588920 0.70 ESR2 (0.53) CES1ESR2PTPN1PTPRCPTPRF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054454-A1 BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE VENKATESAN ARANAPAKAM MUDUMBAI 2009-02-26 US disclosed
US-7276603-B2 serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer WYETH (US) 2007-10-02 US disclosed
EP-1641785-A2 BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS Wyeth (US) 2006-04-05 EP disclosed
US-20050059673-A1 Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use WYETH 2005-03-17 US disclosed
WO-2004099191-A2 BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS WYETH (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054454-A1 BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE TPH1, TPH2, HTR2C CES1 3436/4885ESR2 2644/4885PTPN1 4607/4885
US-20050059673-A1 Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use TPH1, TPH2, HTR2C CES1 3436/4885ESR2 2644/4885PTPN1 4607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.